Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||IMC-3C5||Phase I||Actionable||In a Phase I trial, 50% (4/8) of colorectal cancer patients experienced a progression free survival when treated with IMC-3C5, however, no responses were reported per RECIST (Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 3530).||detail...|
|PubMed Id||Reference Title||Details|
|Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (mab) LY3022856/IMC-3C5 (3C5)||Full reference...|